4 completed, 3 active not recruiting, 1 withdrawn. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 2, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Recurrent Bladder Urothelial Carcinoma: new trials by email Literature Review of Recurrent Bladder Urothelial Carcinoma trials Research Report on Recurrent Bladder Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer Acupuncture Therapy, BCG Solution, Best Practice - Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 45 | 2021-01-22 | 2024-01-02 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer Atezolizumab - Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 172 | 2017-03-13 | 2025-05-22 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Quality-of-Life Assessment - Recurrent Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | Mayo Clinic | 2016-06-01 | 2016-04-18 | |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
Urinary Bladder Neoplasms (6) · Ureteral Neoplasms (5) · Urethral Neoplasms (5) · Carcinoma, Transitional Cell (3)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Urinary Bladder Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Urologic Diseases (6) · Urologic Neoplasms (6) · Ureteral Diseases (5) · Urethral Diseases (5) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3)
Specimen Handling (3) · atezolizumab (3) · Biopsy (2) · 130-nm albumin-bound paclitaxel (1) · Acupuncture Therapy (1) · Albumin-Bound Paclitaxel (1) · Contrast Media (1) · Erlotinib Hydrochloride (1) · Interleukin-7 (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Practice Guidelines as Topic (1) · Standard of Care (1) · Taxes (1) · enfortumab vedotin (1)
National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (2) · Fred Hutchinson Cancer Center (1) · Mayo Clinic (1)
United States (8) · Canada (2)
Anishka A D'Souza (1) · Arlene Siefker-Radtke (1) · Estrella Carballido (1) · Evan Y Yu (1) · Peter C Black (1) · Rohit Jain (1) · Sangeeta Goswami (1) · Sarah P. Psutka (1)
P30CA015704 (2), P30CA015083 (1), P30CA016672 (1), U01CA154967 (1), U10CA180888 (1), UM1CA186644 (1), UM1CA186717 (1)